7月17日，安进盘前上涨3.07%，报374.3美元/股，成交额24.95万美元。消息面上，近期多家投行密集上调安进目标价：瑞银将目标价从400美元上调至420美元并维持买入评级，美银证券将目标价从307美元上调至312美元，Truist Securities将目标价从327美元上调至340美元。此外，摩根士丹利指出下半年生物制药板块将更多由公司基本面驱动，RBC积极评价安进多元化业务布局及新兴管线，市场情绪偏暖。同行业中，艾伯维涨1.02%、吉利德科学涨0.88%，板块整体表现强势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.